Key points from article :
Turn Biotechnologies has successfully delivered mRNA into the dermis, the deepest layer of the skin, without any off-target organ uptake.
This breakthrough is due to the company's proprietary eTurna™ delivery platform, which uses lipid nanoparticles to precisely target mRNA to specific cells.
The eTurna-delivered mRNA formulation remained localized in the injection site and did not distribute to other organs, such as the liver or spleen.
This achievement opens up the possibility of developing new mRNA-based therapies for a variety of skin conditions, including wrinkles, acne, and scars.
Turn Bio is currently completing pre-clinical research on tailored therapies targeting indications in dermatology and immunology.
The company is also developing therapies for ophthalmology, osteo-arthritis, and the muscular system.
